← Back to headlines
Schrödinger Outlines 10%-15% 2026 ACV Growth as Bristol Myers Squibb Deploys Bunsen
Schrödinger projects a 10%-15% growth in its 2026 Annual Contract Value (ACV), coinciding with Bristol Myers Squibb's deployment of its Bunsen platform.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
